# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-170314
Filing Date
2026-04-22
Accepted
2026-04-22 16:01:53
Documents
16
Period of Report
2026-04-22

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | antx-20260422.htm iXBRL | DEF 14A | 1067869
2 | GRAPHIC | img183921429_0.gif | GRAPHIC | 6885
3 | GRAPHIC | img183921429_1.jpg | GRAPHIC | 11099
4 | GRAPHIC | img183921429_2.jpg | GRAPHIC | 11099
5 | GRAPHIC | img183921429_3.jpg | GRAPHIC | 78454
6 | GRAPHIC | img183921429_4.jpg | GRAPHIC | 116556
| Complete submission text file | 0001193125-26-170314.txt |  | 1876391

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
7 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | antx-20260422.xsd | EX-101.SCH | 7582
19 | EXTRACTED XBRL INSTANCE DOCUMENT | antx-20260422_htm.xml | XML | 6031

Mailing Address 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025
Business Address 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41331 | Film No.: 26883643
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)